Pharmaceutical

Avalo drops three rare disease assets amid ongoing challenges

The company will divest the AVTX-800 rare disease compound series to AUG Therapeutics, with an expected completion in Q4 2023.

Sep 13, 2023 - 20:00
Avalo drops three rare disease assets amid ongoing challenges
The company will divest the AVTX-800 rare disease compound series to AUG Therapeutics, with an expected completion in Q4 2023.
Read the original article

Tags:

Previous Article

Opinion: Doctors in the U.S. can learn a lot about advocacy and activism from th...

Next Article

Results from Rybrevant trial solidify Janssen’s foothold in EGFR-mutated NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Flagship, Pfizer team up in deal worth up to $7 billion

STAT+: Flagship, Pfizer team up in deal worth up to $7 ...

Jul 18, 2023

Regeneron is interested in obesity treatments that combat muscle loss

Regeneron is interested in obesity treatments that comb...

Feb 5, 2024

US CDC AdCom recommends lowering the age for pneumococcal vaccines

US CDC AdCom recommends lowering the age for pneumococc...

Oct 26, 2024